Skip to main content
Retour
Watch Compare

Evolus, Inc.

Qualité des données : 100%
EOLS
NASDAQ Manufacturing Chemicals
4,53 €
▼ 0,10 € (-2,16%)
6 months return
—
Momentum
Neutral
5Y revenue growth
31,40%

Croissance

Revenue Growth (5Y)
31,40%
Au-dessus de la moyenne du secteur (1,72%)
Revenue (1Y)11,61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-16,26%
Net Margin-17,38%
Op. Margin-10,99%

Sécurité

Debt / Equity
N/A
Current Ratio2,02
Interest Coverage-1,66

Valorisation

PE (TTM|NTM|2027)
-5,29 | 19,29 | 17,50
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 31,40% annually over 5 years — strong growth
Negative free cash flow of -45,71 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 19,79%
Capital efficient — spends only 1,16% of revenue on capex

Price History

Tendances Financières

Objectif de Cours des Analystes

6 analystes
Buy
+223.8%
upside to target
Actuel
4,53 €
Consensus Target
14,67 €
10,00 €
Bas
20,00 €
Haut
Prévisions
P/E Prévisionnel
19,29
BPA Prévisionnel
0,24 €
CA Est.
388,17 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,12 € · Rev Est: 72,17 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,17 € -0,26 € -0,15 € 0,01 € — —
Estimate -0,14 € -0,09 € -0,18 € 0,04 € -0,12 € -0,05 €
Surprise -18,61% -175,05% +19,38% -64,80% — —

Growth

Rev 5Y: 31,40% · Earnings 1Y: N/A
Revenue Growth (1Y) 11,61% Revenue Growth (3Y) 21,27%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 31,40% Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -17,38%
Revenue (TTM) 297,18 M Net Income (TTM) -51,64 M
ROE N/A ROA -23,06%
Gross Margin 66,33% Operating Margin -10,99%
Net Margin -17,38% Free Cash Flow (TTM) -45,71 M
ROIC -16,26% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,02
Debt / Equity N/A Current Ratio 2,02
Interest Coverage -1,66 Asset Turnover 1,33
Working Capital 68,18 M Tangible Book Value -98,69 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -5,29 · EV/EBITDA: N/A
P/E Ratio -5,29 Forward P/E 19,29
P/B Ratio N/A P/S Ratio 0,92
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,70 Fwd Earnings Yield 5,18%
FCF Yield -16,75%
Market Cap 272,93 M Enterprise Value 375,18 M

Per Share

EPS: -0,80 · FCF/Share: -0,70
EPS (Diluted TTM) -0,80 Revenue / Share 4,57
FCF / Share -0,70 OCF / Share -0,65
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 88,51% · CapEx/Rev: 1,16%
CapEx / Revenue 1,16% FCF Conversion 88,51%
SBC-Adj. FCF -66,48 M Growth Momentum -19,79

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 297,18 M 266,27 M 202,09 M 148,62 M 99,67 M
Net Income -51,64 M -50,42 M -61,69 M -74,41 M -46,81 M
EPS (Diluted) -0,80 -0,81 -1,08 -1,33 -0,94
Gross Profit 197,11 M 182,30 M — — —
Operating Income -32,66 M -34,41 M -49,23 M -65,33 M -44,41 M
EBITDA — — — — —
R&D Expenses — — — — 2,06 M
SG&A Expenses 220,79 M 198,03 M 164,94 M 141,84 M 112,07 M
D&A 7,51 M 5,30 M 5,13 M 3,72 M 5,62 M
Interest Expense 19,69 M 18,74 M 13,83 M 9,10 M —
Income Tax 677 000,0 664 000,0 176 000,0 95 000,0 42 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 225,87 M 232,57 M 189,00 M 177,98 M 257,48 M
Total Liabilities 248,97 M 227,05 M 209,69 M 159,48 M 175,61 M
Shareholders' Equity -23,11 M 5,52 M -20,69 M 18,50 M 81,88 M
Total Debt 146,10 M 121,51 M 120,36 M 71,88 M 71,22 M
Cash & Equivalents 53,83 M 86,95 M 62,84 M 53,92 M 146,26 M
Current Assets 142,92 M 151,34 M 112,42 M 100,80 M 178,80 M
Current Liabilities 75,31 M 62,96 M 48,29 M 46,51 M 57,66 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -5,3 -1,5
P/B — 1,6
ROE % — -54,7
Net Margin % -17,4 -41,5
Rev Growth 5Y % 31,4 1,7
D/E — 0,3

ETFs Holding This Stock
PILL logo PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF
0,62% weight
MXMTX MXMTX
0,13% weight
IJSTX IJSTX
0,13% weight
IJSAX IJSAX
0,13% weight
IJSSX IJSSX
0,13% weight
VPRSX VPRSX
0,13% weight
IJSIX IJSIX
0,13% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0,10% weight
QWVOX QWVOX
0,09% weight
AFSM logo AFSM First Trust Active Factor Small Cap ETF
0,06% weight

Scores de Stratégies

1 strategy matched
Value Price/Sales Ratio Focus (Ken Fisher)
#182 of 245
32

Activité Récente

Entré Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026